BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...SAS hired Daniel Chung as CMO. Chung previously served as therapeutic area leader of ophthalmology at Spark Therapeutics Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...2018 and 2019’s $4.8 billion acquisition of Spark Therapeutics Inc....
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...Jeff Cranmer, Executive Editor The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc....
BioCentury | Jan 7, 2021
Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

...of healthcare ventures at Ziff Ventures and the founding former chairman of gene therapy company Spark Therapeutics Inc....
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...roles in which she will be succeeded by Chairman Faheem Hasnain.Michael Retterath joined gene therapy play Spark Therapeutics Inc....
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

...of gene therapyNovartis’ acquisition of Vedere Bio comes nearly two years after it partnered with Spark Therapeutics Inc....
...an inherited form of blindness caused by mutations in the RPE65 gene. Roche (SIX:ROG; OTCQX:RHHBY) acquired Spark Therapeutics Inc....
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...advantage over a rival program from the Spark Therapeutics Inc....
BioCentury | Oct 14, 2020
Deals

Roche deal sets up capsid developer Dyno for faster growth, push into more therapeutic areas

...payloads. The Swiss pharma, and its Philadelphia-based Spark Therapeutics Inc....
BioCentury | Oct 8, 2020
Product Development

First patient dosed in Phase III hemophilia A trial could narrow gap between Pfizer/Sangamo and BioMarin

...Inc. (NASDAQ:RARE) partnered with Bayer AG (Xetra:BAYN), and RG6357 from Roche (SIX:ROG; OTCQX:RHHBY) via the Spark Therapeutics Inc....
BioCentury | Aug 29, 2020
Deals

Data Bytes: Cryoport deals show continued interest in cell, gene therapy manufacturing and supply chain players

...expand its cell and gene therapy offerings, which include the Advanced Therapy Shipper product line. Amanda Micklus Spark Therapeutics Celgene...
Items per page:
1 - 10 of 263
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...SAS hired Daniel Chung as CMO. Chung previously served as therapeutic area leader of ophthalmology at Spark Therapeutics Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...2018 and 2019’s $4.8 billion acquisition of Spark Therapeutics Inc....
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...Jeff Cranmer, Executive Editor The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc....
BioCentury | Jan 7, 2021
Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

...of healthcare ventures at Ziff Ventures and the founding former chairman of gene therapy company Spark Therapeutics Inc....
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...roles in which she will be succeeded by Chairman Faheem Hasnain.Michael Retterath joined gene therapy play Spark Therapeutics Inc....
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

...of gene therapyNovartis’ acquisition of Vedere Bio comes nearly two years after it partnered with Spark Therapeutics Inc....
...an inherited form of blindness caused by mutations in the RPE65 gene. Roche (SIX:ROG; OTCQX:RHHBY) acquired Spark Therapeutics Inc....
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...advantage over a rival program from the Spark Therapeutics Inc....
BioCentury | Oct 14, 2020
Deals

Roche deal sets up capsid developer Dyno for faster growth, push into more therapeutic areas

...payloads. The Swiss pharma, and its Philadelphia-based Spark Therapeutics Inc....
BioCentury | Oct 8, 2020
Product Development

First patient dosed in Phase III hemophilia A trial could narrow gap between Pfizer/Sangamo and BioMarin

...Inc. (NASDAQ:RARE) partnered with Bayer AG (Xetra:BAYN), and RG6357 from Roche (SIX:ROG; OTCQX:RHHBY) via the Spark Therapeutics Inc....
BioCentury | Aug 29, 2020
Deals

Data Bytes: Cryoport deals show continued interest in cell, gene therapy manufacturing and supply chain players

...expand its cell and gene therapy offerings, which include the Advanced Therapy Shipper product line. Amanda Micklus Spark Therapeutics Celgene...
Items per page:
1 - 10 of 263